OverviewChartNewsTraderScreen

ALMIRALL S.A. EO -,12/  ES0157097017  /

Frankfurt
5/10/2024  8:08:02 AM Chg. +0.1000 Volume Bid9:54:31 PM Ask9:54:31 PM High Low
8.9400EUR +1.13% 0
Turnover: 0.0000		 -Bid Size: - -Ask Size: - 8.9400 8.9400
GlobeNewswire 4/16 Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
GlobeNewswire 3/13 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermat...
GlobeNewswire 3/5 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire 1/10 Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
GlobeNewswire 11/14/2023 Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
GlobeNewswire 11/14/2023 Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for de...
GlobeNewswire 10/5/2023 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
GlobeNewswire 9/21/2023 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire 9/18/2023 Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire 9/12/2023 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire 9/7/2023 Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire 3/25/2022 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo...
GlobeNewswire 3/16/2022 Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire 3/15/2022 ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
GlobeNewswire 3/14/2022 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
GlobeNewswire 3/8/2022 Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire 3/2/2022 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire 3/1/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2/1/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 1/3/2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 12/16/2021 China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire 12/1/2021 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 11/10/2021 Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire 11/8/2021 Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
GlobeNewswire 11/4/2021 Athenex Provides Third Quarter 2021 Corporate and Financial Update